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This article will provide a pathophysiologic basis for the assessment of critically ill children
who have developed disorders of urine volume. The anatomical and pathophysiologic causes
of oliguria and polyuria are considered. The physiologic basis for the use of urinary sodium
and osmolarity as a guide to the assessment of patients with disorders of urine volume are
discussed in detail. In addition, guidelines for the management of children with acute renal
failure, with particular emphasis on the consideration for nutritional support ofthese patients,
is discussed as a part of the comprehensive approach to this problem. This article emphasizes
an understanding ofthepathophysiology ofsalt and water excretion bythe kidney as a founda-
tion to the diagnosis and management of patients with oliguria and polyuria.
In a critically ill patient, the volume or rate of urine excretion is used, frequently,
as an index of cardiovascular stability, cardiac output, and peripheral perfusion. In
fact, in some instances, the adequacy of parenteral fluid therapy is assessed and ad-
justed according to urine output. Such assumptions concerning urine output and
judgments about fluid therapy are not only an oversimplification of complex renal
physiology, but also hazardous for patient management. Under homeostatic condi-
tions, 20-25 percent ofcardiac output is distributed to the kidneys, 500 cc/minute in
an adult. Approximately 20 percent ofthis volume is filtered by the glomerulus (100
cc/minute) and, over 24 hours, the proximal tubule is presented 144 liters of
glomerular filtrate (i.e., potential urine) and 20,160 mEq (460 g) of sodium. The
tubules and collecting ducts reabsorb 98-99 percent ofthis filtrate (i.e., 142 liters of
fluid and 456 g ofsodium) which results in a final urine output of2 liters/day which
contains 4 g of sodium. In most circumstances, the kidney will react to maintain in-
travascular volume and plasma tonicity by balancing the processes of filtration,
reabsorption, and excretion. For example, by autoregulation of resistance in the af-
ferent and efferent arteriole, glomerular filtration rate (GFR) can be maintained
through a wide range of blood pressures and renal perfusion [1]. Moreover, the in-
tact kidney responds to a variety of stimuli in a reasonably predictable and
reproducible manner so that an assessment of urinary electrolytes can be helpful in
evaluating patients with oliguria or polyuria.
However, pathophysiologic alterations in the production or reabsorption of
tubular fluid render urine output a poor index of renal function. If GFR is main-
tained but the reabsorptive processes are enhanced by a reduction in intravascular
volume, as in simple dehydration, or diminished renal perfusion, as occurs in con-
gestive heart failure, a patient may be relatively oliguric while renal function is quite
normal. Alternatively, GFR may be severely reduced but a concomitant reduction in
the volume of tubular fluid which is reabsorbed will result in a normal or increased
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urinary volume. In fact, in the extreme example of non-oliguric acute renal failure
(ARF), the amount of urine excreted may equal the entire volume of glomerular
filtrate produced. Thus, it becomes apparent that the oliguric patient may have
relatively normal renal function and the polyuric patient could have acute or chronic
renal failure. Assessment of renal function in children and adolescents must be
based, therefore, on absolute values or changes in the blood levels of urea nitrogen
(BUN) and creatinine (Cr) and/or the clearance of creatinine or inulin [2,3].
In a stable, euvolemic state, a child or adolescent with normal renal function and
intact kidneys will generally excrete 1.5-3 cc/kg/hour of urine. This estimate is
derived from the volume ofurine expected in a pediatric patient receiving parenteral
fluids at a maintenance rate of infusion. Maintenance fluid therapy is designed to
maintain water and electrolyte homeostasis with minimal renal compensation [4].
The volume of fluid needed for maintenance therapy is composed of two parts: (1)
evaporative (insensible) losses and (2) urinary losses. Evaporative or insensible water
requirement is approximately one-third of total maintenance requirement and con-
sists of electrolyte-free water. During maintenance fluid therapy, urinary losses are
expected to have an osmolarity of300 mOsm/L and a specificgravity of 1.010. Cau-
tion must be taken that the patient can achieve an isotonic urine and, under
homeostatic conditions, urinary losses account for two-thirds of total maintenance
fluid requirement. Estimates of total maintenance requirement can be made from
the following table:
1-10 kg 100 cc/kg/day
11-20 kg 1,000 cc + 50 cc/kg > 10/day
21-80 kg 1,500 cc + 20 cc/kg > 20/day
This sliding scale approach is based on the concept that water and electrolytes are
lost in direct proportion to the kilocalories expended. If 120 ml of water is required
for every 100 Kcal metabolized and if water of oxidation is 17 ml/100 Kcal and
preformed water is 3 ml/100 Kcal, it becomes apparent that, in this system, 100 ml
of water are needed for each 100 Kcal expended. Thus, the calculations from the
sliding scale provided an estimate of caloric expenditures, maintenance fluid re-
quirements, and expected urine volume under homeostatic conditions.
ASSESSMENT OF OLIGURIA
Based on the expected urine volume, a child or adolescent excreting less than 0.8
cc/kg/hour of urine should be assessed for oliguria. Classically, the causes of
oliguria have been divided into pre-renal, renal, and post-renal categories. However,
such a classification is neither physiologically based nor accurate. Accordingly, the
classification shown in Table 1 forms the basis of our approach to this problem.
Anatomic Causes First consideration should be given to the obstruction or oc-
clusion of the major anatomical components of the renal system: artery, vein,
ureter, and bladder. It must be emphasized that oliguria will not result from the oc-
clusion of the artery, vein, or ureter to only one kidney, unless the contralateral
kidney is absent or non-functional. Thus, one must suspect bilateral renal artery,
vein, or ureteral obstruction ifthese sites are to be implicated as the cause ofoliguria.
Renal artery thrombosis is rare in children although occasionally encountered in
newborn infants as a complication of umbilical artery catheterization. The usual
clinical presentation for this problem is acute hypertension in a young infant.




A. Obstruction or occlusion of major anatomical sites:
1. Both renal arteries
2. Both renal veins
3. Both ureters
4. Bladder outlet
B. Pathophysiologic response to:
1. Decreased intravascular volume or impaired renal perfusion
2. Fixed or established renal insult-acute renal failure
3. Non-physiologic anti-diuretic hormone secretion
Likewise, renal vein thrombosis occurs almost exclusively in newborn infants. This
diagnosis should be suspected when a patient develops an enlarging flank mass
associated with the onset of hematuria, proteinuria, thrombocytopenia, and in-
travascular coagulopathy. The diagnosis ofrenal vein thrombosis maybe difficult to
establish and may requirearteriography for confirmation. Bilateral ureteral obstruc-
tion should be considered in all children who develop oliguria because this is a
potentially acutely correctable situation. Because partial ureteral obstruction pro-
duces polyuria and because most children with hydronephrosis present with an ab-
dominal mass or urinary tract infection, ureteral obstruction is an uncommon cause
of oliguria. Nonetheless, this possibility should be evaluated using non-invasive im-
aging techniques such as renal ultrasound [5,6]. The demonstration of two kidneys
and the lack of a dilated renal pelvis in, at least, one kidney will essentially eliminate
this diagnosis as the cause of oliguria. Several prospective studies have shown renal
ultrasound to be reliable in assessing acute ureteral obstruction in adults [5,6].
Unless this diagnosis is highly suspected because of the clinical situation, potentially
more risky or invasive procedures such as intravenous or retrograde pyelogram
should not be done routinely. Lastly, bladder outlet obstruction must be evaluated
in all children with oliguria, particularly male infants. In this condition, the bladder
can be palpated quite often in children, especially boys with posterior urethral
valves. Even ifthe bladder cannot be palpated, acatheter should be inserted into the
bladder to rule out this potentially correctable cause of oliguria. If the patient has a
bladder catheter it should be irrigated. Each of these anatomic sites should be con-
sidered prior to evaluation of the physiologic causes of oliguria.
Pathophysiologic Causes There are three pathophysiologic conditions in which
oliguria occurs: (1) decreased intravascular volume or impaired renal perfusion, (2)
acute renal failure, and (3) non-physiologic anti-diuretic hormone secretion. The
renal response in each of these clinical settings is highly reproducible and well de-
fined. Although each of these conditions will cause a fall in urine volume below ex-
pected levels, the urinary constituents, especially sodium and osmolarity, are
characteristic and can be used diagnostically when the kidney has not been
manipulated pharmacologically with vasodilators or diuretics (Table 2).
Decreased Intravascular Volume or Impaired Renal Perfusion
A decrease in intravascular volume results in a decrease in cardiac output and
renal hypoperfusion. Thus, the renal response to either decreased intravascular
volume or a primary fall in renal perfusion is similar. In this situation, the renal
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TABLE 2
Urinary Sodium and Osmolarity in Evaluation of Oligo-Anuria
Decreased Intravascular
Volume or Diminished Established Non-Physiologic
Renal Perfusion Acute Renal Failure ADH Secretion
Urinary
Na mEq/L <10 >50 >50
Fractional
Na Excretion
(FENa) <1% >2% >2%
Urinary
osmolarity
mOsm/L >500 -300 >500
Urine omlrt Plasm osmolarity > 1.5 0.8-1.2 >2.0
BUN/serum
creatinine >20 Progressive increase <20
in both
Urine Urine
Fractional Sodium Excretion =Plasma Na + Plasma Creatinine
tubules remain intact and a marked increase in the reabsorption of solutes and water
occurs throughout the nephron. An increase in filtration fraction (GFR/renal
plasma flow) produces an increase in peritubular oncotic pressure and results in
enhanced reabsorption of tubular fluid in proximal tubular segments. The decrease
in renal perfusion stimulates the secretion of renin by the juxtaglomerular ap-
paratus, and thereby aldosterone production is increased and produces sodium reab-
sorption from the distal tubule. Release of anti-diuretic hormone in response to de-
creased intravascular volume increases water reabsorption in the collecting duct.
Thus, the urinary sodium concentration is quite low (< 10 mEq/L) and the urinary
osmolarity is high (> 500 mOsm/L). In premature infants and children less than
one year of age, urinary sodium < 20 mEq/L and osmolarity < 400 mOsm/L
would be expected values [7]. If the patient is hyponatremic (serum sodium 130
mEq/L), then fractional sodium excretion (FENa) is a more accurate index of renal
sodium handling. Fractional sodium excretion is the amount of sodium excreted
(UNa x V) expressed as a ratio of the amount of sodium filtered (GFR x PNa). If
one substitutes creatinine clearance (UCr X V/Pcr) for GFR, the FENa can be ex-
pressed as U/PNa . U/Pcr. Similarly, urine-to-plasma ratio ofosmolarity is a better
reflection of water reabsorption in the hyponatremic patient. For example, if a pa-
tient had a serum sodium of 120 mEq/L, the estimated plasma osmolarity would be
240 mOsm/L, and a urine osmolarity of 360 mOsm/L would be a urine/plasma
osmolar ratio of 1.5 and would represent significant water reabsorption. The in-
creased solute reabsorption which occurs in this condition pertains to constituents
other than just sodium, such as urea. Normally, 30 percent of filtered urea is reab-
sorbed, and an increased proportion is reabsorbed when renal perfusion falls. Since
creatinine is not reabsorbed by the tubule, the enhanced urea reabsorption results in
a BUN-to-creatinine ratio > 20, which is often referred to as "pre-renal" azotemia,
but is actually due to the pathophysiologic response ofthe kidney to diminished per-
fusion. Renal perfusion may be reduced to the extent of impairing GFR, at which
time serum creatinine will rise. In contrast to patients with an established acute renal
failure where the serum creatinine increases by 0.5-1.5 mg/dl each day, patients
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with impaired renal perfusion tend to have a slower rise in serum creatinine such that
the values tend to remain at the same level for several days at a time and to increase
in a stepwise fashion rather than a linear pattern.
Clinical conditions which are associated with decreased intravascular volume in-
clude dehydration secondary to vomiting, diarrhea, nasogastric drainage, or third
space losses. Repletion of intravascular volume with appropriate fluid therapy in
this clinical setting will result in increased urine output. Occasionally, children with
nephrotic syndrome will become oliguric while edematous because of decreased in-
travascular volume secondary to reduced plasma oncotic pressure. Remission of the
nephrotic syndrome or the infusion of albumin to restore intravascular volume will
alleviate the oliguria in these children. Patients with congestive heart failure have a
primary decrease in renal perfusion because of diminished cardiac output despite
adequate or expanded intravascular volume. In this situation, therapy should be
aimed toward improved cardiac function rather than repletion of intravascular
volume. Similarly, children with acute glomerulonephritis [8,9,10,11,12,13] or
hemolytic uremic syndrome [14,15,16,17,18] have increased intravascular volume
but diminished renal perfusion which occurs at a level of the glomerular capillary
loop. In patients with acute glomerulonephritis, the increase in renal vascular
resistance is caused by the intense inflammatory reaction in the glomeruli and in pa-
tients with hemolytic uremic syndrome micro-thrombi occlude the glomerular
capillaries. The oliguria associated with these conditions resolves only as the renal
disease improves and heals. In both of these "renal" causes, the tubules remain intact
and the renal response in terms of urinary sodium concentration and osmolarity is
physiologically identical to the "pre-renal" causes such as dehydration and con-
gestive heart failure. Thus, the use of the term "pre-renal" to describe the renal
pathophysiologic response to decreased intravascular volume or diminished renal
perfusion is inaccurate and confusing. Lastly, patients with the hepato-renal syn-
drome will have oliguria and urinary sodium concentrations which are low and
urinary osmolarity which is high. In fact, it would appear that this syndrome is a
vasomotor phenomena rather than an intrinsic renal lesion. The correction of the
oliguria in these patients occurs only when the liver failure improves, which is rare.
Acute Renal Failure (ARF)
The renal response to a fixed or established acute renal insult is complex
[19,20,21,22]. Although the specific mechanisms involved may vary according to the
type and intensity of the acute renal injury, an acute loss of GFR and paralysis of
tubular function are the characteristic features of acute renal failure (ARF). An in-
crease in renal vascular resistance [23,24] combined with back-leak of tubular fluid
[25,26,27,28,29] and intratubular obstruction [30,31,32,33] result in a nearly com-
plete cessation of GFR. Clinically, this is reflected in an increase in both BUN and
serum creatinine on a daily basis. It is important to remember that although GFR is
virtually non-existent early in ARF, the absolute value of serum creatinine will not
reflect the profound loss of GFR because this value increases only 0.5-1.5
mg/dl/day. Thus, in patients with ARF, the rate of change in serum creatinine,
rather than the actual value itself, is the best index of the level of GFR, and a pro-
gressive increase in BUN and creatinine is a characteristic feature of this syndrome.
Changes in BUN will be affected by a variety of factors such as catabolic rate, pro-
tein load, and medications, including steroids and antibiotics. Consequently, the
rate of change in BUN is not a specific index of the level of GFR. The second feature
which is characteristic of ARF is diminished tubular function. Ironically, the term
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"acute tubular necrosis" is a better description of tubular function than anatomic
morphology in ARF [34]. Thus, the small volume of urine which these patients pro-
duce has a high sodium concentration (> 50 mEq/L) and elevated FENa (> 2 per-
cent). Since both the concentration and dilution of tubular fluid require intact
tubular function, these patients have urine which is isotonic to plasma (i.e., urinary
osmolarity of 280-300 mOsm/L and urine-to-plasma osmolar ratio of 0.8-1.0). In
ARF, a dilute urine would be as unexpected as a concentrated urine and an isotonic
urine is the most consistent feature of this syndrome. In fact, a low urinary sodium
concentration and FENa have been reported in some patients with ARF induced by
contrast media.
The clinical conditions which are associated with the development ofARF include
hypotension/shock, renal ischemia, nephrotoxins, drugs, hyperuricemia, asphyxia,
and sepsis [35,36,37,38,20,39]. Most often, more than one potential causative agent
can be identified, but in some circumstances, ARF will develop without a clearly
defined renal insult. In this regard, several factors should be remembered: (a)
dehydration or volume depletion will increase the susceptibility to develop ARF
from a minor insult [40,41]; (b) hypoxia combined with acidosis will produce a more
profound loss of renal function than either factor alone; (c) nephrotoxins, especially
aminoglycoside antibiotics, usually produce a non-oliguric ARF initially with
oliguria developing later in the course of the renal injury [42,43,40,44], and some
drugs may potentiate the relative nephrotoxicity of other agents [45]; and (d) sepsis
may produce ARF from endotoxins without concomitant hypotension [46].
Studies in both experimental animals [47,48,49,50,51] and man [52,53,54] have
indicated that the fall in GFR can be attenuated significantly or even eliminated by
administration ofsaline, mannitol, furosemide, or other agents prior to the renal in-
sult. Interestingly, the common denominator among all oftheseperturbations which
will protect against the development of ARF is the initiation of a solute diuresis
prior to the renal injury [51,55,56]. Thus, in those clinical situations where an acute
renal insult is anticipated, such as renal vascular surgery, open heart surgery using
cardiopulmonary by-pass, or administration oflarge volumes ofcontrast media, the
patient should be well hydrated with isotonic fluid and/or a natriuretic agent should
be given prior to the renal insult.
At the present time, the treatment of ARF consists of supportive care until the
kidney recovers from the acute insult. In this regard, several potential problems
must be anticipated and managed: (1) fluid therapy, (2) electrolyte problems, (3)
acidosis, (4) hypertension, (5) dialysis, and (6) nutrition. For the child with oliguric
ARF, fluid therapy should be designed to replace extra-renal fluid losses. In large
part, this means providing adequate fluids to account for evaporative (insensible)
fluid requirements plus losses from other sources such as nasogastric drainage,
chest-tube drainage, or urine output, if any. Evaporative or insensible losses are
composed ofsolute-free water which is lost through the skin and lungs. This water is
utilized for thermal regulation and tohumidifytheinspired air. Under ordinary con-
ditions, these losses are approximately 30-35 percent of total maintenance volume
[4]. Sweat is not included in evaporative fluid losses. Because insensible losses are
evaporative, the ambient humidity and temperature will have profound effects on
the magnitude of these losses. Patients receiving humidified air via a nasotracheal
tube or dwelling in a mist tent will have a considerable reduction in insensible losses,
which must be taken into account in calculating maintenance needs. Similarly, pa-
tients with hyperthermia or tachypnea or under a radiant warmer will have exag-
34DISORDERS OF URINE VOLUME
gerated evaporative losses. Under ordinary circumstances, 33 percent ofevaporative
losses occur through the lungs and 66 percent from the skin, while total evaporative
losses are one-third ofmaintenance requirements. The volume of fluid calculated to
replace evaporative losses should be given as an electrolyte-free solution. Fluids lost
from other sources should be replaced in amounts equal to those being excreted with
a solution similar in composition to that being lost only if the patient is not
edematous, volume overloaded, hypertensive, or in congestive heart failure. The
adequacy of fluid therapy in patients with ARF is judged best by changes in body
weight and serum sodium concentration. Ifan appropriate volume and composition
of fluid have been administered, the weight of the patient should decrease by 0.5-1
percent per day because of caloric requirement, and the serum sodium should re-
main stable between 130-140 mEq/L. A more rapid loss of weight or increase in
serum sodium would suggest that inadequate fluids had been given, while a gain in
weight combined with a fall in serum sodium would imply overhydration. If hydra-
tion has been inadequate, one should assess those factors which would increase in-
sensible fluid losses such as hyperthermia, increased activity (particularly seizures),
tachypnea, or adry ambient environment such as that produced by radiant warmers.
If excessive fluids have been given, one should re-evaluate insensible fluid require-
ment in terms of factors which would reduce evaporative fluid losses, such as
humidified air from a respirator, hypothermia, sedation, or reduced activity.
Two major electrolyte problems are encountered commonly in patients with ARF.
Hyponatremia (serum sodium < 130 mEq/L) may be present at the time the
diagnosis ofARF is made or may occur during the course oftherapy. When present
at the onset of ARF, hyponatremia is usually the result of overzealous administra-
tion of fluids in an attempt to increase urine output prior to the recognition of
oliguric ARF. When a fall in serum sodium occurs during the management ofachild
with ARF, it is usually because ofan overestimate ofevaporative fluid requirement.
In both cases, hyponatremia has occurred because of excessive administration of
fluids and not the excretion of sodium. If the hyponatremia is profound (serum
sodium < 120 mEq/L) and the patient has central nervous system manifestations
such as obtundation or seizures, arapid correction ofthe hyponatremia would be in-
dicated and the serum sodium can be increased by 10 mEq/L with the infusion of
hypertonic (3 percent) saline. This solution contains 450 mEq/L of sodium, and 12
ml/kg will increase serum sodium by 10 mEq/L. It must be emphasized that (1) the
administration of sodium is not usually required to correct the hyponatremia
associated with ARF, (2) fluid restriction is the primary and essential mode of
therapy, and (3) the infusion ofsodium maybe hazardous for the patient and lead to
volume expansion, hypertension, and congestive heart failure.
Because the kidney is the primary source for potassium excretion and because the
extra-renal mechanisms which are required for potassium adaptation occur slowly
over several weeks, hyperkalemia is frequently encountered in patients with ARF
157]. Often the insult which causes the ARF produces significant systemic tissue
damage with the release ofintracellular potassium from necrotic cells or in response
to acidosis. Since potassium ions move out ofcells as hydrogen ions move into cells,
serum potassium levels are not a direct index of total body potassium and must be
interpreted with respect to acid-base status. For example, a serum potassium of 6
mEq/L is less ominous in a patient with a mild metabolic acidosis (pH 7.30; bicar-
bonate, 15 mEq/L) than in a patient with a metabolic alkalosis (pH 7.50; bicar-
bonate, 35 mEq/L). Despite the same level of serum potassium, the patient with
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alkalemia would be expected to have a larger total body burden of potassium.
Largely because of its cardiac toxicity, hyperkalemia represents a life-threatening
complication of ARF and must be treated promptly and aggressively. If mild elec-
trocardiographic changes such as peaked T-waves are present, the administration of
sodium bicarbonate (1-2 mEq/kg over 10-30 minutes) or Kayexalate (1 g/kg/dose)
by mouth or enema may be effective in reducing serum potassium levels. Kayexalate
is a sodium polysterene-sulfonate resin which exchanges sodium for potassium. It
has the advantage of net potassium removal, with the disadvantage of sodium
delivery and fecal impaction if not excreted. If significant electrocardiographic
changes such as widened QRS complex or arrhythmia are present, the infusion of 10
percent calcium gluconate solution (0.5-1 ml/kg) over 5-10 minutes with electrocar-
diographic monitoring or the administration of an insulin (0.2 units/kg/hour) and
glucose solution (1 g/kg/hour) should be started. Although these solutions will
lower the serum potassium level acutely and prevent a fatal cardiac arrhythmia, their
effectiveness is transient because they do not result in net potassium removal. Con-
sequently, these modalities are used until other therapies such as dialysis can be
started. Finally, either hemo or peritoneal dialysis should be instituted if
hyperkalemia is severe (serum potassium > 8 mEq/L) or intractable.
A mild metabolic acidosis associated with an increased anion gap is an inevitable
consequence of reduced renal function because of the retention of hydrogen ions,
sulfate, and phosphate. Ordinarily, this mild acidosis can be easily compensated by
respiratory mechanisms and does not require specific intervention. If the acidosis is
contributing to the development of hyperkalemia or respiratory compensation is im-
paired, sodium bicarbonate can be administered. Generally halfthe estimated deficit
(20 - serum bicarbonate) is replaced: ½/2 deficit x weight in kg x 0.5 = mEq Na
HCO3 to be given. When sodium bicarbonate is infused, three points of caution
should be remembered: (a) standard bicarbonate preparations contain approxi-
mately 1 mEq HCO3 per ml, are, therefore, hypertonic solutions, and must be given
slowly to avoid marked changes in plasma tonicity and central nervous system com-
plications, (b) bicarbonate is an effective buffer only if the CO2 produced from the
reaction H + HCO3 is removed by adequate ventilation. Thus, in situations in
which ventilation is impaired, the infusion of bicarbonate will have little net buffer-
ing effect until ventilation is adequate. In those clinical settings in which a severe
acidosis persists because of poor tissue perfusion or a lactic acidosis develops,
dialysis may be necessary to correct the acidosis, (c) patients with ARF frequently
have hyperphosphatemia with mild hypocalcemia, and rapid correction of acidosis
with the development of alkalemia can induce tetany or seizures.
Hypertension is frequently encountered in children with acute renal failure. While
judicious administration of fluids will lessen the degree and frequency of hyperten-
sion in children with ARF, a substantial proportion of patients will require treat-
ment to avoid developing hypertensive encephalopathy. The management of
hypertensive crisis or accelerated hypertension requires special consideration in
children [58]. Heart failure, papilledema, and/or encephalopathy mandate prompt
and intensive antihypertensive treatment. Hypertensive encephalopathy in children
may be manifested as headache, irritability, or convulsions. These symptoms appear
to be related more to the rapidity ofthe rise in blood pressure than to a specific level
of pressure. Papilledema and retinal hemorrhages and exudates are less commonly
seen in children with acute symptomatic hypertension than in adults [59]. Children
with acute elevations in blood pressure may convulse and yet not manifest
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papilledema or significant funduscopic changes. Diazoxide, a non-diuretic
sulfonamide derivative, is the drug of choice for the treatment of acute or ac-
celerated hypertension in children [60]. It should be administered rapidly (in less
than 30 seconds) in an intravenous dose of 5 mg/kg/dose (maximum, 300 mg per
dose). The onset of action is rapid and the effect on blood pressure dramatic. The
patient rarely becomes hypotensive, and the effect may last several hours to a day,
during which time additional medications, such as hydralazine, can be added to ob-
tain long-term control of blood pressure. Repeated administration of diazoxide may
be associated with sodium retention, and prolonged use should, therefore, be com-
bined with a natriuretic drug, such as furosemide; frequently, a combination of a
diuretic, such as furosemide, and diazoxide are used from the onset.
Parenterally administered hydralazine (0.2 mg/kg/dose, intramuscularly or in-
travenously) is also an effective and potent antihypertensive agent [58]. Its onset of
action is one to two hours, and its duration of action is four to eight hours. Unfor-
tunately, nausea, vomiting, and headache commonly occur in children treated with
parenteral hydralazine, and these side effects may confuse the clinical picture when
hypertensive encephalopathy is present. In situations in which intravascular volume
overload is the prominent factor and renal function is relatively well preserved, such
as acute glomerulonephritis [61], intravenous administration of furosemide (2 to 10
mg/kg/dose) may prompt a brisk diuresis and concomitant lowering of the blood
pressure. Sodium nitroprusside is a potent and effective parenterally administered
antihypertensive [62]. This drug must be dissolved in 5 percent dextrose solution and
given as a continuous infusion with the dose and rate ofinfusion titrated against the
arterial blood pressure. A dose of1 pg/kg/minute is usually effective in producing a
prompt fall in pressure. In patients with renal insufficiency, the blood levels of a
metabolic product, thiocyanate, must be carefully monitored. The drug should be
discontinued if the thiocyanate levels reach or exceed 10 mg/dl; this metabolic prod-
uct can be removed by dialysis.
In those patients with symptomatic severe hypertension (i.e., hypertensive crisis),
treatment should be initiated with diazoxide, given intravenously. A response should
be seen in 5 to 15 minutes; if there has been no effect in 30 to 60 minutes, the dose
should be increased by 25 to 50percent to a maximum dose of300 mg, and repeated.
Concomitantly, furosemide is usually administered intravenously, unless the patient
is anephric or has been anuric for a prolonged period. If these measures are ineffec-
tive and the patient remains symptomatic, treatment with sodium nitroprusside
should be instituted. In asymptomatic children with severe hypertension but without
overt hypertensive crisis, treatment can be initiated with parenterally administered
hydralazine. The dose ofthis medication can be increased by 50 to 100 percent every
one to two hours (to a maximum dose of 15 mg) until the desired effect has been
achieved. Once the blood pressure has been controlled acutely, a long-term
therapeutic regimen must be instituted.
The indications for the initiation of dialysis in patients with ARF remain con-
troversial. Although several investigators have suggested that dialysis should be
started "early" and the BUN maintained below 100 mg/dl, there is no clear evidence
to support this approach as the routine management of all patients with ARF. It is
generally agreed that certain complications of ARF would be absolute indications
for dialysis: (1) severe orpersistenthyperkalemia; (2) intractable hypertension, con-
gestive heart failure, orpulmonaryedema fromvolumeoverload; (3) severe and per-
sistent acidosis; and (4) neuromuscular instability or uremia. In most cases,
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however, dialysis should be initiated prior to the onset of one ofthese complications
of ARF. The decision to start dialysis therapy in a patient with ARF should depend
on an assessment of the clinical setting for each patient and an anticipation of the
period of ARF based on the type and severity of renal insult which has occurred.
This treatment modality should not be initiated because of artificial criteria such as
the level of BUN, number of days of oliguria, level of serum creatinine, and so on.
In large part, such decisions require an understanding of the potential benefit and
risk of dialysis as well as an appreciation of the natural history of ARF in various
clinical situations and should not be based on arbitrary criteria which may not
reflect the level of renal function or degree of uremia. With the development of
refined techniques for enteral and parenteral nutrition, dialysis has become an im-
portant adjunct for the support of nutritional requirements of patients with ARF.
Although hemodialysis is technically feasible even in neonates [63], peritoneal
dialysis is frequently more practical because it alleviates the need for vascular access.
Both modalities of dialysis are comparably effective in the management of patients
with ARF and the choice of a specific technique will depend on (1) size of the pa-
tient, (2) availability ofvascular access, (3) integrity oftheperitoneal membrane and
abdominal cavity, and (4) local experience and expertise.
Nutritional support for the patient with ARF must be given serious attention. The
insult which causes the ARF frequently renders the patient severely catabolic. Re-
cent data would suggest that healing and repair of the kidney, as well as other
organs, require the provision of adequate calories and energy metabolism
[64,65,66]. Because of volume restriction secondary to oliguria, the supply of meta-
bolic substrate is severely limited in patients with ARF. In this regard, it is important
to remember that a 5 percent glucose solution given at a maintenance rate over
twenty-four hours provides only 20 percent of basic calorie needs, i.e., "protein-
sparing" calories. Thus, when the rate of infusion is reduced, as occurs in oliguric
ARF, the proportion of caloric expenditures provided falls dramatically unless the
caloric content of the infusate is increased. In 1967, Lee et al. [67] treated 45 adult
patients with intravenous casein hydrolysates and lipid emulsion for 6 to 31 days
during an episode of ARF. These investigators observed diminished weight loss and
more prompt recovery in this group of patients. Subsequently, several investigators
[68,69,70] demonstrated that the intravenous infusion of essential amino acids and
glucose would result in positive nitrogen balance, better healing of wounds,
maintenance of weight, amelioration of uremic symptoms, and diminished levels of
blood urea nitrogen in post-operative adult patients with ARF. In 1973, Abel and
associates [71] provided controlled evidence of the efficacy of the administration of
essential amino acids with hypertonic glucose in ARF. These investigations com-
pared the outcome of28 patients treated with amino acids and hypertonic glucose to
25 patients given an isocaloric, isovolemic glucose infusion. Patients with congestive
heart failure, endocarditis, hepatic failure, sepsis, persistent hypertension, or
urinary obstruction were excluded from the study. In addition, the two groups were
randomized for factors which might alter the course of ARF such as age, levels of
BUN or creatinine prior to treatment, oliguria, and the interval from injury to in-
travenous therapy. In this relatively homogenous group of patients, the infusion of
amino acid with hypertonic glucose had a dramatic effect on recovery from the
episode of ARF. During the period of acute renal shutdown, the mortality rate was
reduced from 56 percent in the glucose-treated patients to 25 percent in the patients
receiving amino acids and glucose. Among thepatients who required dialysis only 18
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percent of those given glucose lived, whereas 65 percent of those treated with the
amino acid-glucose mixture survived. In patients given amino acids, the serum
creatinine concentration peaked on day two of therapy while this value continued to
rise for seven days after initiation of treatment with glucose alone. Utilizing a
slightly different amino acid mixture, in a larger group of 129 patients, Baek and
associates (72] also noted an impressive decline in mortality from 70 percent in
glucose-treated patients to 46 percent in patients given amino acids during an
episode of post-operative ARF. In 1975, Leonard and co-workers [73] reported im-
proved nitrogen balance but no effect on survival or duration of renal insufficiency
in a small group of 20 patients with ARF treated with amino acids and glucose or
glucose alone. Unfortunately, this was a heterogenous group of both medical and
surgical patients, and the treatment groups were not randomized for factors which
might alter the outcome. In fact, the amino acid-glucose-treated patients were older,
had more pre-existing disease, and were more catabolic prior to initiation of
therapy. Similarly, Abel et al. [74] failed to demonstrate increased survival with
amino acid therapy for patients with acute renal failure complicated by congestive
heart failure, hepatic failure, sepsis, or persistent hypertension. Unfortunately,
there was no glucose-treated control group with similar complications. Thus, the
results of administration of amino acids to patients with ARF is mixed. One possible
explanation would be that the potential effect of this therapy in the more severely ill
patients is obscured because of their heightened catabolic state and the limited abil-
ity to supply calories and nutrients which can be utilized for renal repair and
regeneration. Because of limited clinical experience and conflicting reports concern-
ing the efficacy of this modality, definitive indications for initiation of amino acid
therapy in ARF cannot be established. The potential beneficial effect of increased
caloric and nutrient content must be evaluated in the context of a given patient's
clinical setting, local expertise in the performance of parenteral alimentation in
children and adolescents, and the risks of this procedure, which include catheter
placement injuries, sepsis, hyperglycemia, and electrolyte abnormalities [72,73].
It should be remembered that children may be able to take enteral nutrition during
an episode of ARF. In such circumstances, the diet should be modified to account
for the ARF, but the caloric intake should be maximized to offset the catabolic state
associated with ARF. In large part, this will consist of restricting protein intake to
0.5-1g/kg/day, limiting sodium to 2 g/day, and reducing potassium to 1.5 g/day.
Although fluid intake will be restricted, free access to carbohydrates and fats should
be encouraged. Once dialysis is initiated, the dietary and fluid restriction can be
liberalized, or if continuous peritoneal dialysis is used, the diet can be relatively
unrestricted. Thus, clinical judgments concerning nutritional needs and dialysis
therapy must be made together and individualized, based on a specific clinical set-
ting and needs of the patient.
Some patients will develop ARF without oliguria [42,44]. In the clinical setting of
non-oliguric ARF, the urine constituents are the same as those in oliguric patients,
but the etiology is more often related to nephrotoxic antibiotics, particularly the
aminoglycoside category [43]. Experimental data would suggest that non-oliguric
ARF develops when cortical perfusion is better preserved relative to total renal
blood flow [40]. Although it has been proposed that potent diuretics can convert an
oliguric ARF to a polyuric ARF, such therapy does not seem warranted for several
reasons: (a) the use of furosemide and ethycrinic acid in high doses in patients with
ARF is associated with significant and sometimes permanent hearing loss [75,76],
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(b) conversion from oliguric to polyuric ARF does not result in morerapid return of
GFR [75,76], and (c) the eventual prognosis is unchanged [75,76]. In patients with
non-oliguric ARF, careful replacement ofurine losses must be incorporated into the
fluid management regime to avoid electrolyte disturbances.
The prognosis for patients with an established acute renal insult is dependent
largely on the cause of ARF. With the availability of acute hemo and peritoneal
dialysis for the replacement of kidney function, it is apparent that patients die with,
not because of, ARF. Thus, the magnitude and severity of the total body insult
become the limiting factors for most patients with ARF [77,78]. Recovery from
oliguric ARF is heralded by an increase in urine output which occurs, on average, 10
to 14 days after the acute injury. In some situations the period of oliguria may be
only two to three days, whereas some patients have ARF for 30 days or more. It is
relatively difficult to predict the onset of recovery and, for patients with prolonged
oliguria, the potential for recovery of renal function is even more difficult to assess.
Once urine output reappears, there is usually an increase in volume for several days
as GFR returns faster than tubular function and a significant diuresis may ensue.
The BUN and serum creatinine does not usually fall until the diuresis has been
established for several days. However, data from experimental animals [26] and
man [27] would suggest that a significant amount of solute and water leaks back
across the injured tubular epithelium during the early phase of recovery from ARF.
Thus, the back leak of tubular fluid containing urea and creatinine across the tubule
into the blood would result in the BUN and serum creatininebeing an underestimate
of GFR during the early period of recovery from ARF. The recovery of renal func-
tion is dependent on reperfusion of the previously vasconstricted kidney
[47,79,80,24]. Thus, care must be taken to assure the maintenance of intravascular
volume, cardiac output, and renal perfusion to promote recovery from ARF. In this
regard, the diuresis which occurs during this phase of ARF should be replaced unless
the patient has clear clinical signs of volume overload or edema formation.
Moreover, drugs or procedures which may result in diminished renal perfusion
should be avoided if possible. Most patients have a full recovery of renal function,
although maximal concentrating ability may be impaired for several years
[77,81,78].
Non-Physiologic Anti-Diuretic Hormone Secretion
Oliguria may be a mode of presentation for critically ill children with non-
physiologic (inappropriate) anti-diuretic hormone (ADH) secretion because of the
low renal solute load in these patients. Although this pathophysiologic process is fre-
quently thought to be complex and clinically confusing, it is based on a relatively
simple concept: the persistent excretion of a concentrated urine in the absence of
physiologic stimuli for ADH release. If conceptualized from this perspective, the
clinical findings in this syndrome are easy to understand, and the term non-
physiologic ADH secretion is a clearer description of the syndrome than the more
conventional term "syndrome of inappropriate ADH secretion" (SIADH). The
secretion of ADH by the posterior lobe of the pituitary gland is closely regulated,
under homeostatic conditions, by osmolar and volume receptors. A 2 percent in-
crease in plasma osmolarity will result in the release of enough ADH to produce
anti-diuresis [82], while a 1.2 percent decrease in plasma osmolarity will suppress
ADH secretion sufficiently to produce a diuresis [83]. Baroreceptors, located in the
carotid sinus [84] and left atrium [85] modulate ADH release in response to changes
in intravascular volume. Although these physiologic monitors usually act in the
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same direction, there is evidence that regulation of volume takes precedence over
osmolarity when the two parameters conflict. Patients with non-physiologic ADH
secretion have a persistently concentrated urine even though intravascular volume is
normal or increased and plasma osmolarity is normal or decreased. Continual
release of ADH results in increased water reabsorption from the collecting duct into
the plasma. Consequently, these patients have a concentrated urine (urine osmolar-
ity > 500 mOsm/kg, urine-to-plasma osmolar ratio of 2.0) and a diluted plasma
(plasma osmolarity < 280 mOsm/L, serum sodium < 140 mEq/L, BUN < 15
mg/dl, and uric acid < 2 mg/dl). The reabsorption ofwater from the collecting duct
into the plasma also results in intravascular volume expansion which causes a
depression of proximal tubular sodium reabsorption and a natriuresis (urinary
sodium > 50 mEq/L, FENa > 2 percent). Several aspects ofthis sequence of events
require additional clarification: (a) neither the retention of water nor the quantity of
sodium lost in the urine can completely account for the profound hyponatremia
which may occur in some patients, and it has been proposed that some sodium enters
cells where it becomes osmotically inactive [86]; (b) hyponatremia occurs only when
excess free water has been administered and retained; conversely, if predominantly
isotonic fluid is given or fluid is restricted early, hyponatremia may not occur [87];
(c) in the face of severe hyponatremia, urine osmolarity may not be very high but the
urine will not be maximally dilute (less than 100 mOsm/L) and, therefore, is inap-
propriately concentrated relative to plasma osmolarity [87]. Thus, when a patient
has a persistently concentrated urine despite a fall in serum sodium and osmolarity
combined with an elevated urine sodium concentration, the diagnosis of non-
physiologic ADH secretion should be entertained: the normal or low serum
osmolarity indicates that the osmolar receptors are not stimulated and the increased
urine sodium implies that intravascular volume is replete or expanded; therefore, the
baroreceptors are not stimulated and, thus, the persistently concentrated urine must
be the result of non-physiologic ADH secretion.
This syndrome was described first in patients with bronchogenic carcinoma [88].
Subsequently, a variety ofclinical conditions have been associated with this process.
In the intensive care setting, this syndrome is frequently seen in patients with
pulmonary problems [89] (pneumonia, ventilator therapy), intracranial lesions [90]
(tumor, trauma, meningitis), in post-operative patients [87], and secondary to drugs
(vincristine, chlorpropamide, cyclophosphamide, morphine) [91]. It is important to
remember that emotional stress and pain may cause the release of ADH, and in
some patients no cause will be evident. The anticipation of the development of this
syndrome in appropriate clinical settings has important implications for fluid
therapy. In patients with meningitis, head trauma, or after general anesthesia, only
one-half to two-thirds of usual maintenance fluids should be given, since it is likely
that serum ADH levels will be high and, consequently, the patients will not be able
to dilute their urine to specific gravity 1.010 or less.
Since the primary determinant of this syndrome is persistent reabsorption of
water with consequent dilution of plasma and intravascular volume expansion, the
principal mode of therapy is fluid restriction. The clinical complication of this syn-
drome, particularly hyponatremia, can be entirely prevented by fluid restriction
even though there is persistent secretion of ADH. In fact, in most patients, fluid
restriction alone is sufficient to correct hyponatremia and should be considered the
basis of therapy. In cases of severe hyponatremia, hypertonic (3 percent) saline
should be given to acutely raise serum sodium in order to diminish central nervous
system complications such as coma or convulsions. Hypertonic saline infusion
41results in additional volume expansion and diminished proximal sodium reabsorp-
tion so that the effectiveness of this therapy is transient, at best, and may result in
hypertension or congestive heart failure. The combination of potent diuretic agents
and hypertonic fluid infusions may be effective in patients with severe hyponatremia
[92]. The diuretic agents produce urine which contains 75-100 mEq/L of sodium
and chloride. Thus, the infusion of a more hypertonic solution in a volume equal to
the urine output should result in an increase in serum sodium without additional
volume expansion. Because of the rapid shifts in fluids and electrolytes which occur
with this therapy, it should be instituted with caution. Other therapeutics have been
used in patients with chronic SIADH [93], but these are rarely applicable for acutely
ill patients.
Throughout this approach to the assessment of a child or adolescent with oliguria,
we have emphasized the use of urinary sodium concentration and osmolarity as an
integral part ofthe diagnostic process. In this regard, two important factors must be
underscored. The urinary sodium concentration and osmolarity are a valid index of
the pathophysiologic cause ofoliguria only ifthe urine sample is obtained beforethe
patient has been given: (1) a significant fluid challenge (20 cc/kg/hour) or (2)
diuretic agents (mannitol, furosemide, ethycrinic acid). In some situations, one may
not be able to differentiate the cause for the oliguria, and two manipulations can be
attempted. First, assuming that the patient does not have overt evidence of fluid
overload such as pulmonary or peripheral edema, a volume challenge (20
cc/kg/hour) of isotonic fluid should be administered. Since the fluid is isotonic, the
potential hyponatremia associated with a fixed renal injury or non-physiologic ADH
secretion should not be exacerbated and the patient with oliguria secondary to
volume depletion or diminished renal perfusion should manifest an increase in urine
output. Similarly, the administration of furosemide (4 mg/kg/intravenously) would
be expected to result in a diuresis in patients with volume depletion but would have
little or no effect for patients with ARF. It must be remembered that both of these
maneuvers will invalidate the use of urinary sodium concentration, FENa, or urinary
osmolarity in differentiating the cause of oliguria.
ASSESSMENT OF POLYURIA
The development of urine output which exceeds expected values (> 4
cc/kg/hour) is termed polyuria. Children are considerably more susceptible to the
problems of volume overload and the development of polyuria in response to in-
creased intravascular volume because small volumes of fluid can produce a greater
degree of volume expansion in children than they can in adults. This condition re-
quires careful evaluation and may arise from two major sources: (1) excretion of a
fluid load or (2) atubular defect for sodium and/or water reabsorption. As shown in
Table 3, an assessment ofthe changes in the plasma values ofsodium and osmolarity
compared with these same values in the urine may be quite helpful in evaluating the
possible causes of polyuria. In polyuric patients, the urinary concentration of
sodium and osmolarity must be interpreted in the context of the sodium concentra-
tion and osmolarity of the fluids being administered to the patient. Thus, specific
values for serum and urine sodium and osmolarity have not been given in Table 3,
but relative changes have been indicated.
Excretion ofFluid Load
If a patient has received an excess volume of fluid which must be excreted (20
cc/kg/hour or twice maintenance fluid requirement), the patient will appear clini-
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cally well hydrated and the changes in plasma and urinary constituents will depend,
to some extent, on the type of fluid load which has been given. Because ofconcomi-
tant expansion ofthe intravascular space, one would expect an increase in urinary so-
dium concentration and an FENa> 1 percent early inthe course of avolume-induced
diuresis irrespective of the tonicity of fluid given. Ifhypertonic solutions are given,
plasma osmolarity would increase, ADH would be released, and a large volume of
concentrated (hypertonic) urine would be excreted. If the fluid given is isotonic to
plasma, the resultant diuresis would be isotonic. When hypotonic solutions are in-
gested, serum osmolarity falls, ADH secretion is suppressed, and a large volume of
dilute urine is produced. Late in the course ofexcretion of a hypotonic volumeload,
the urine sodium concentration will fall as intravascular volume expansion is cor-
rected. Most often, polyuria which arises from excretion of a fluid load occurs
because of inadvertent or overzealous fluid therapy. In evaluating such patients, all
fluids given to the patient, including intra-operative fluids, must be carefully
scrutinized. Therapy for this problem is clearly to restrict fluids and allow the pa-
tient to excrete the volume load already administered.
Defect in Salt and/or Water Reabsorption
The second category of causes for polyuria is a tubular defect in salt and/or water
reabsorption. In contrast to the patients who areexcreting avolumeload and appear
clinically well hydrated, patients in this category will maintain ahigh urine flow rate
despite appearing clinically volume-depleted. In patients with a salt-losing nephrop-
athy, a defect in maximal urinary concentrating ability is usually also present, and
these patients excrete a large volume of a urine with an increased sodium content
and with an isotonic osmolarity even when intravascular volume is low or renal
perfusion diminished. This type of renal tubular defect may be due to anatomic
(cystic diseases, partial ureteral occlusion), pathologic (interstitial nephritis, non-
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oliguric ARF, recovery phase of oliguric ARF, post-obstructive diuresis, DKA),
or pharmacologic (osmotic diuresis, loop-acting diuretics, drugs) lesions. In most in-
stances, the specific cause for the salt and water diuresis will be apparent from the
associated clinical findings. The major complications associated with these causes of
polyuria are related to fluid and electrolyte abnormalities, particularly hyponatre-
mia, if urine losses are replaced with hypotonic solutions; hypokalemia and
hypocalcemia occur because of the excess urinary loss of these electrolytes, and
dehydration/hypotension develops because of the limited concentrating ability.
Therapyis aimed atthe specific cause whichis identified andthe replacement offluid
losses to prevent volume depletion.
Diabetes insipidus (DI) is a tubular defect in water reabsorption due to a lack of
ADH release from the posterior pituitary (central DI) or a failure of the kidney to
respond to ADH (nephrogenic DI) [93]. In either case, polyuria occurs because of
the inability to re-claim tubular fluid presented to the collecting duct. Consequently,
these patients produce a persistently dilute urine which has a low urinary sodium
concentration since there is no defect in sodium reabsorption. The excretion oflarge
volumes of dilute urine results in hypernatremia and hypertonicity of plasma. In
many respects, this syndrome is defined as the inverse of non-physiologic ADH
secretion: the production of a persistently dilute urine despite increasing serum
sodium and osmolarity. Central DI may result from an injury to the posterior pitui-
tary where ADH is stored or the hypothalamus where ADH is produced. Central DI
has been associated with head trauma, meningitis, tumors, and cerebral edema.
Since the renal tubule is intact, these patients respond to ADH or one ofits analogs,
1-desamine-8D-arginine vasopressin (dDAVP), by producing a concentrated urine.
When central DI is fully established, it is difficult to administer sufficient fluids to
maintain the patient in a homeostatic state, and ADH should be given. Care must be
taken to adjust fluids appropriately once ADH is effective to avoid wide and rapid
swings in serum sodium. Because of greater dependability, aqueous pitressin or
dDAVP are preferred to pitressin tannate in oil. dDAVP can be used only if the
nasopharyngeal mucosa is intact.
Nephrogenic DI results in the same perturbations in serum and urine sodium and
osmolarity as may be seen inpatients with central DI [93]. Patients with nephrogenic
DI have a tubular insensitivity to ADH which may be either hereditary or secondary
to drugs [82] (methoxy-flurane, propoxyphene, lithium, or demethyl-chlortetra-
cycline), renal parenchymal disease (chronic glomerulonephritis, sickle cell ne-
phropathy), or electrolyte abnormalities (hypokalemia or hypercalcemia). Therapy
should be directed toward elimination of the secondary causes of nephrogenic DI
when possible and reduction in the renal solute load to diminish the degree of
diuresis. Patients with the sex-linked hereditary disorder will require management
with diuretics or prostaglandin synthetase inhibitors.
This article has outlined an approach to the assessment of critically ill children
who have developed disorders ofurine output. We have emphasized an understand-
ing ofthe pathophysiology ofsalt and water excretion bythe kidney as a foundation
to the diagnosis and management of patients with oliguria and polyuria. Based on
this approach, the causes of disorders of urine output should be readily diagnosed
and effectively treated.
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